329 related articles for article (PubMed ID: 27504842)
1. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
[TBL] [Abstract][Full Text] [Related]
2. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
4. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
5. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
7. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
8. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
Kronick J; Gabril MY; House AA
Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
[TBL] [Abstract][Full Text] [Related]
9. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
10. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
11. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
12. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis.
Monich AG; Cunha MFMD; Barreto FC
J Bras Nefrol; 2023; 45(4):503-505. PubMed ID: 37497829
[No Abstract] [Full Text] [Related]
14. Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma.
Rabenou RA; Charles HW
AJR Am J Roentgenol; 2015 Aug; 205(2):292-301. PubMed ID: 26204278
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
16. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands.
Eijkemans MJ; van der Wal W; Reijnders LJ; Roes KC; van Waalwijk van Doorn-Khosrovani SB; Pelletier C; Magestro M; Zonnenberg B
Am J Kidney Dis; 2015 Oct; 66(4):638-45. PubMed ID: 26165440
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
18. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analyses of bilateral renal angiomyolipomas associated with tuberous sclerosis complex].
Huang Z; Li H; Ji Z; Xiao H
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):935-7. PubMed ID: 24854916
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
